Clinical Trial Disclosure: Global Overview and Implications of New Laws and Guidelines

被引：0

作者：

Kathy B. Thomas

Merete Joergensen

Gerard Lynch

Michael Rubison

Brandon D. Porter

Jacqueline Sayers

Claudia Tesch

机构：

[1] Medical and Scientific Writing and Publication Services,Global Clinical Registry

[2] Novo Nordisk A/S,Global Process Owner

[3] Trial Transparency,Global Regulatory Affairs

[4] Flint Hills Consulting,Product Development Quality, Roche Products Ltd.

[5] LLC,undefined

[6] Johnson & Johnson Pharmaceutical Research & Development,undefined

[7] LLC,undefined

[8] Welwyn Garden City,undefined

[9] Nycomed Deutschland GmbH,undefined

来源：

Drug information journal : DIJ / Drug Information Association | 2010年 / 44卷

关键词：

Clinicaltrials.gov; EMEA; EudraPharm; EudraCT; FDA Amendments Act of 2007 WHO;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Clinical trial disclosure has received much international attention. The US Congress has enacted the Food and Drug Administration Amendments Act of 2007 (FDAAA), also known as Public Law 110-85. Section 801 of FDAAA requires public registration of new or ongoing clinical trials and disclosure of results for completed clinical trials on the public database ClinicalTrials.gov. FDAAA has provisions for proof of compliance and authorizes penalties for noncompliance; several phases will be implemented over 3 years and completed by 2010.

引用

页码：213 / 225

页数：12

共 50 条

[1] Clinical Trial Disclosure: Global Overview and Implications of New Laws and Guidelines
Thomas, Kathy B.
Joergensen, Merete
Lynch, Gerard
Rubison, Michael
Porter, Brandon D.
Sayers, Jacqueline
Tesch, Claudia
DRUG INFORMATION JOURNAL, 2010, 44 (03): : 213 - 225
[2] Clinical trial results of new therapies for HBV: Implications for treatment guidelines
Gish, RG
SEMINARS IN LIVER DISEASE, 2005, 25 : 29 - 39
[3] Operational Issues in Clinical Trial Disclosure of Global Trials
Pelletier, Shawn M.
Strange, Maureen A.
Godlew, Barbara J.
DRUG INFORMATION JOURNAL, 2010, 44 (03): : 253 - 264
[4] Operational Issues in Clinical Trial Disclosure of Global Trials
Shown M. Pelletier
Maureen A. Strange
Barbara J. Godlew
Drug information journal : DIJ / Drug Information Association, 2010, 44 (3): : 253 - 264
[5] Clinical Implications of New Cholesterol Guidelines
Halloran, Laurel
JNP-JOURNAL FOR NURSE PRACTITIONERS, 2014, 10 (10): : 870 - 871
[6] Behaviour within a Clinical Trial and Implications for Mammography Guidelines
Kowalski, Amanda E.
REVIEW OF ECONOMIC STUDIES, 2023, 90 (01): : 432 - 462
[7] Evolution laws and new trends of global LNG pricing and their implications
Chen Rui
Qi Pengfei
Hang Xiaoyu
Li Chunxia
NATURAL GAS INDUSTRY B, 2021, 8 (05) : 475 - 483
[8] Evolution laws and new trends of global LNG pricing and their implications
Chen R.
Qi P.
Zhang X.
Li C.
1600, Natural Gas Industry Journal Agency (41): : 144 - 152
[9] Overview of the new ERS Clinical Practice Guidelines Methodology Network
Vaccaro, Valerie
Cruz, Joana
BREATHE, 2022, 18 (04)
[10] Perspectives and implications of the new sepsis clinical practice guidelines
McCormack, Denise
Kulkarni, Miriam
Keller, Steven E.
JOURNAL OF THORACIC DISEASE, 2016, 8 (10) : E1355 - E1357

← 1 2 3 4 5 →